Citigroup upgraded shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) from a neutral rating to a buy rating in a research note published on Friday, Marketbeat reports. They currently have $4.50 price objective on the stock.
A number of other research firms have also weighed in on LRMR. William Blair reiterated an outperform rating on shares of Larimar Therapeutics in a research note on Tuesday, August 15th. JMP Securities reiterated a market outperform rating and issued a $17.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday, August 15th.
Larimar Therapeutics Trading Down 4.6 %
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. UBS Group AG boosted its holdings in Larimar Therapeutics by 8,152.8% in the 1st quarter. UBS Group AG now owns 5,942 shares of the company’s stock valued at $27,000 after purchasing an additional 5,870 shares during the period. California State Teachers Retirement System bought a new stake in shares of Larimar Therapeutics during the 2nd quarter worth $27,000. Wells Fargo & Company MN lifted its holdings in shares of Larimar Therapeutics by 4,797.5% during the 2nd quarter. Wells Fargo & Company MN now owns 9,795 shares of the company’s stock worth $31,000 after acquiring an additional 9,595 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Larimar Therapeutics by 836.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 11,822 shares of the company’s stock worth $38,000 after acquiring an additional 10,560 shares during the last quarter. Finally, American International Group Inc. bought a new stake in shares of Larimar Therapeutics during the 2nd quarter worth $39,000. 91.92% of the stock is owned by institutional investors.
Larimar Therapeutics Company Profile
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease.
- Five stocks we like better than Larimar Therapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- The most upgraded stocks in November have two things in common
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Monday.com rocked earnings like it’s the weekend
- Following Congress Stock Trades
- Plan to own one retailer? Make it this one
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.